Eddie Pan

Eddie Pan

Expertise: Institutional Investments, Insider Activity, Disruptive Innovations

Education: BBA, Finance, James Madison University

About Eddie:
Eddie Pan specializes in institutional investments and insider activity. He has been enamored with hedge funds since he began investing and regularly collaborates with industry executives to craft editorial pieces. Tracking the investments of institutional investors and insiders can provide a vast array of knowledge that is scarcely covered.

After receiving his BBA in Finance from James Madison University, Eddie began his career at Accenture as an analyst. Today, he writes for InvestorPlace’s Today’s Market team, which centers on the latest news involving popular stocks.

Eddie got his start in the financial media world by publishing articles on top-performing hedge funds and their investment strategies on Substack. He still publishes pieces on his Substack today.

Common Stocks and Uncommon Profits by Philip A. Fisher is Eddie’s favorite investment book. Fisher’s 15 Points have heavily influenced his investment strategy.

Recent Articles

Rivian Stock Alert: 2 Big Reasons RIVN Shares Are Crashing Today

Shares of Rivian stock are having a volatile week after the EV company reported price hikes. Rivian also received two price target downgrades.

What Are the Top Nancy Pelosi Stocks to Watch After the State of the Union Address?

Interest in Nancy Pelosi stocks have skyrocketed after the conclusion of the State of the Union address. Here's what Pelosi has been trading.

Retail Owns the Float: What to Know About the #AMCArmy Claims Moving AMC Stock Today

AMC stock fans are in full force after CEO Adam Aron claimed retail investors own 90% of the public float, excluding index funds.

Is TGT Stock a Buy After Earnings? 3 Analysts Weigh In on Target Price Predictions.

Target rallied on Tuesday after reporting impressive revenue and earnings. Does that mean TGT stock is a buy right now?

DNAC Stock: 11 Things to Know Ahead of the ProKidney SPAC Merger

Palihapitiya's SPAC with ProKidney is expected to close during Q3 of this year. Here's what you need to know about the biotech company.